Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARRC Trial: Pembrolizumab and Radiation vs. Chemotherapy and Radiation for High-Grade T1 Bladder Cancer
NCT06770582Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2025
- Primary completion
- Feb 2032
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in bladder cancer (2 arms), sponsored by National Cancer Institute. Primary endpoints: Bladder intact event-free survival at 5 years and Global quality of life at 5 years. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06770582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770582.